Antiviral drugmaker Gilead is rumored to be in price negotiations in India for its new hep. C pill Sovaldi (sofosbuvir). The Hindu Business Line reports that the biotech is looking to introduce Sovaldi into India’s marketplace.
Twelve weeks of the treatment costs $84,000 in the US, but the framework for a deal in India is far different: the company is said to be looking to price its locally produced version of the medication at around $2,000 for six months of therapy. The company is in talks with patient advocacy groups.